NCT07289763

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

Conditions

• Primary Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	SHR-2173 injection	SHR-2173 injection, with a total of 8 administrations
DRUG	SHR-2173 injection	SHR-2173 injection, with a total of 16 administrations
DRUG	SHR-2173 injection	SHR-2173 injection , with a total of 32 administrations

Timeline

• Start date: 2025-12-31
• Primary completion: 2027-08-01
• Completion: 2027-09-01
• First posted: 2025-12-17
• Last updated: 2026-01-26

Locations

1 site across 1 country: China